MedTrace Logo

Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer

NCT01591590 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-10-26

No results posted yet for this study

Summary

The purpose of this study is to assess whether in a population of patients with advanced colorectal cancer for which no known effective therapy is available, measuring the spontaneous evolution of tumoral metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion MRI are able to measure it.

Conditions

Interventions

OTHER

FDG PET-CT

All patients will undergo FDG PET-CT at inclusion and 2 weeks after

OTHER

Diffusion MRI

All patients will undergo Diffusion MRI at inclusion and 2 weeks later

OTHER

Blood samples (plasma preparation and CTC)

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Amélie Deleporte, MD · Jules Bordet Institute , Universite Libre De Bruxelles

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2019-07-31
Completion
2021-09-25

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591590 on ClinicalTrials.gov